Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802242 | 0.84 | COMT (0.42) | KMT2AMAPTCOMTALDH1A1 | |
| SCHEMBL7803359 | 0.77 | COMT (0.32) | KMT2AMAPTCOMTALDH1A1HPGD | |
| SCHEMBL2732554 | 0.77 | KMT2A (0.56) | KMT2AMAPTCOMTALDH1A1HPGD | |
| SCHEMBL6899340 | 0.75 | KMT2A (0.34) | KMT2A | |
| SCHEMBL24417705 | 0.73 | ALDH1A1 (0.43) | KMT2AMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL21720446 | 0.73 | ALDH1A1 (0.32) | MAPTCOMTALDH1A1 | |
| SCHEMBL21718752 | 0.73 | MAPT (0.30) | MAPTCOMT | |
| SCHEMBL21720478 | 0.73 | KMT2A (0.38) | KMT2A | |
| SCHEMBL21720319 | 0.73 | KMT2A (0.38) | KMT2A | |
| SCHEMBL10280655 | 0.73 | COMT (0.30) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | UNIV EMORY (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | UNIV EMORY (US) | 2023-11-09 | — | — | US | disclosed |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | EMORY UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | EMORY UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20210361631-A1 | N-methyl-D-aspartic Acid Receptor Modulators | UNIV EMORY (US) | 2021-11-25 | — | — | US | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9133182-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, GPR119 | KMT2A 2620/4885MAPT 2495/4885COMT 3278/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | KMT2A 3866/4885MAPT 2725/4885COMT 3189/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | KMT2A 3866/4885MAPT 2725/4885COMT 3189/4885 |
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | KMT2A 3195/4885MAPT 2594/4885COMT 3674/4885 |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | KMT2A 1592/4885MAPT 34/4885COMT 265/4885 |
| US-20210361631-A1 | N-methyl-D-aspartic Acid Receptor Modulators | GRIN1, GRIN2A, GRM1 | KMT2A 907/4885MAPT 357/4885COMT 546/4885 |
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | PDE10A, PDE3A, PDE2A | KMT2A 2177/4885MAPT 4100/4885COMT 858/4885 |
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | GRIN1, GRIN2A, GRM1 | KMT2A 839/4885MAPT 347/4885COMT 524/4885 |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | KMT2A 4292/4885MAPT 3808/4885COMT 3810/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | KMT2A 2680/4885MAPT 2572/4885COMT 4612/4885 |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | CREBBP, TEAD1, SREBF1 | KMT2A 1636/4885MAPT 3850/4885COMT 3944/4885 |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | GRIN1, GRIN2A, GRM1 | KMT2A 907/4885MAPT 357/4885COMT 546/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | KMT2A 3195/4885MAPT 2594/4885COMT 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.